Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Rush

Kraemer

Sackeim

; ACNP Task Force. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006; 31: 1841-1853.

FDA. Esketamine prescribing information. Accessed October 1, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s003lbl.pdf

Ochs-Ross

Daly

Zhang

. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry. 2020; 28: 121-141.

Daly

Trivedi

Janik

. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019; 76: 893-903.

Wajs

Aluisio

Holder

. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020; 81: 19m12891.

Antidepressant Effect of Prolonged Twice-Weekly Intranasal Esketamine Treatments after Nonresponse to Electroconvulsive Therapy in a Patient with Treatment-Resistant Depression

Abstract

Get full access to this article

References